Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537545 | 0.77 | MYB (0.45) | MYBALDH1A1USP7MAPTKMT2A | |
| SCHEMBL5048527 | 0.75 | HSD17B10 (0.52) | MYBALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL5045119 | 0.67 | MEN1 (0.56) | MYBALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL5045714 | 0.65 | MYB (1.00) | MYBMAPTKMT2ANPSR1L3MBTL1 | |
| SCHEMBL15363767 | 0.65 | ALDH1A1 (0.67) | MYBALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL19124952 | 0.59 | MAPT (0.56) | ALDH1A1MAPTKMT2AHSD17B10TSHR | |
| SCHEMBL1226812 | 0.58 | DHFR (0.35) | — | |
| SCHEMBL5959230 | 0.55 | NPC1 (0.81) | ALDH1A1MAPTKMT2AHSD17B10TSHR | |
| SCHEMBL157603 | 0.54 | CES2 (0.42) | KMT2ATSHRMEN1 | |
| SCHEMBL9162427 | 0.51 | DCPS (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | Ruprecht-Karls-Universität Heidelberg (DE) | 2018-11-22 | — | — | US | disclosed |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9371333-B2 | Chromene derivatives and their analoga as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 142/4885ALDH1A1 3782/4885USP7 3639/4885 |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885ALDH1A1 4092/4885USP7 3542/4885 |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | WNT3, WNT1, WNT3A | MYB 152/4885ALDH1A1 4092/4885USP7 3542/4885 |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 172/4885ALDH1A1 3312/4885USP7 2592/4885 |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885ALDH1A1 4092/4885USP7 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.